Streetbeat News

Revenues

WEAV

Analysts have recently updated their ratings and price targets for Weave Communications (NYSE:WEAV), showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $15.75, up from $11.50, indicating a positive outlook on the company's future performance. Weave Communications, known for its integrated communications platform, has shown a revenue growth rate of 20.19% as of September 30, 2023, but its growth rate is lower than the industry average in the Information Technology sector. Despite this, the company's net margin and return on equity (ROE) surpass industry standards, showcasing strong financial health.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 2:01 pm

AEE

Ameren (NYSE:AEE) has been evaluated by 5 analysts over the last three months, showing a mix of opinions. Recent ratings include 2 somewhat bullish and 3 indifferent, with a shift in sentiment observed in the last 30 days. The average 12-month price target for AEE is $77.2, a slight decrease from the previous $78.25. Analysts from firms like BMO Capital and Barclays have adjusted their ratings and price targets, reflecting changes in market conditions and Ameren's performance. Despite a -10.67% revenue decline, Ameren maintains a strong net margin of 23.93% and above-average ROE and ROA, indicating effective cost management and financial performance.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 2:01 pm

GDRX

GoodRx Holdings (NASDAQ:GDRX) has received mixed analyst ratings over the past three months, with a recent shift towards a more positive outlook. The average 12-month price target for GDRX has increased to $6.75, up 9.4% from the previous $6.17. Analysts from Leerink Partners, RBC Capital, Truist Securities, and B of A Securities have updated their ratings and price targets, reflecting varied expectations for the company's performance. GoodRx, a digital healthcare platform, faces challenges in revenue growth and market capitalization but excels in net margin, ROE, and ROA, indicating strong financial health and efficient asset management.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 2:01 pm

DOCS

Doximity (NYSE:DOCS) has been analyzed by 5 analysts in the last three months, showing a unanimous indifferent stance with all 5 ratings being neutral. The 12-month price targets for Doximity have been updated, with an average target of $29.8, marking a 15.73% increase from the previous average of $25.75. The company's financial performance is strong, with a notable revenue growth rate of 17.37%, a net margin of 35.45%, and an ROE of 5.52%. Doximity's market capitalization and financial metrics indicate a robust market presence and financial health.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 2:01 pm

CVS

Five analysts have recently reviewed CVS Health (NYSE:CVS), showing a mix of bullish and somewhat bullish sentiments, with a shift towards more conservative ratings in the last 30 days. The average 12-month price target for CVS is now $90.4, down 3.83% from the previous average, with targets ranging from $84.00 to $99.00. CVS Health's financial performance is strong, with significant revenue growth, high net margin, and effective debt management, positioning it well in the healthcare sector.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 2:00 pm

PDCO

Patterson Cos (NASDAQ:PDCO) has been analyzed by 5 analysts, showing a mix of somewhat bullish and indifferent ratings. The average 12-month price target is now $33.00, down from $36.75, indicating a 10.2% decrease. Analysts from Leerink Partners, Goldman Sachs, Piper Sandler, and Morgan Stanley have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Patterson Cos, a leading dental and animal health distributor, shows strong financial health with notable revenue growth, net margin, ROE, and ROA, despite a lower market capitalization compared to industry peers.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 2:00 pm

BABA

NVDA

RIVN

TSLA

Cryptocurrencies trade mixed as Dogecoin mirrors 2023 bull market patterns, and Bitcoin's potential post-halving correction could target $40K. Rivian rebounds in premarket trading. Analysts predict a pause in US stock rally and discuss potential impacts of a second Trump presidency. International tensions rise with US-China relations and covert operations in Ukraine. Tech sector sees Nvidia's upside potential and Alibaba's optimism, while electric vehicle companies like Tesla and Rivian make headlines. Broadcom nears a strategic sale, and financial deals include Ant Group's acquisition of Credit Suisse's China unit.

Portfolio Pulse from Akanksha Bakshi

February 26, 2024 | 1:46 pm

CNEY

CN Energy Group has announced its preliminary revenue forecast for Q1 2024, estimating revenues to be between $21.0M and $22.0M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:42 pm

SPY

USA Building Permits for the month were reported at 1.489M, slightly above the estimated 1.470M but below the previous month's 1.493M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:35 pm

SPY

USA Building Permits for the month showed a decrease of 0.3%, which is better than the estimated -1.5% and a decline from the previous 1.8%.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:35 pm